Related Experiment Video
Updated: Jul 10, 2026

10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Blastic mantle cell leukemia: a previously undescribed form
C H Dunphy1, J C Hancock, J J Rodriguez
1Department of Pathology, St. Louis University Health Sciences Center, Missouri, USA.
Journal of Clinical Laboratory Analysis
|May 14, 1999
Summary
Mantle cell leukemia, a rare blood cancer, typically involves small lymphocytes. This case report describes a unique blastic morphologic variant, previously undocumented in the leukemic phase of mantle cell lymphoma.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma.
- The leukemic phase, termed mantle cell leukemia (MCL), is defined by specific lymphocyte counts and morphology.
- While blastic variants of MCL exist, a blastic morphologic variant of MCL has not been previously described.
Observation:
- A 74-year-old male presented with splenic rupture and an elevated white blood cell (WBC) count.
- Peripheral blood examination revealed lymphocytes with blastic morphology.
- Diagnostic workup included flow cytometric immunophenotyping and cytomorphology.
Findings:
- The case presented a rare blastic morphologic variant of mantle cell leukemia.
- Diagnosis was confirmed through immunophenotyping and cytomorphology, identifying the blastic nature in the leukemic phase.
- This represents the first documented instance of a blastic morphologic variant in the leukemic phase of MCL.
Implications:
- This finding expands the known morphologic spectrum of mantle cell leukemia.
- It highlights the importance of considering blastic morphology in the differential diagnosis of leukemic B-cell lymphomas.
- Further research may elucidate the clinical behavior and treatment implications of this rare variant.
More Related Videos
Related Concept Videos
Lineage Commitment
Commitment is the process whereby stem cells:
Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

